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Stem cell therapies in brain diseases
have in recent years met with a mix
of both disappointing and encouraging
news. The road taken from the early
high hopes and great promises for such
treatment to the current more sober-
ing experiments have been cumbersome
but also highly instructive and reward-
ing. Thus, new technologies for delivery
and for obtaining progenitor cells and spe-
cific classes of neurons including bone
marrow cells and induced Pluripotent
Stem (iPS) cells have been developed and
carry with them renewed interests and
hopes for stem cell treatments (Banerjee
et al., 2014; Inoue et al., 2014). Successful
stem cell application in the brain, how-
ever, still have some obstacles and draw-
backs that are related to the absence
of international consensus procedures for
stem cell derivation, the characterization
and management for their transplanta-
tion in clinical trials/animal models of
neurodegenerative diseases. More atten-
tion paid to these missing links by sci-
entists could positively influence outcome
after grafting and enable direct compar-
isons between studies done in different
Institutes.
Along this line the recent paper by
Viero et al. (2014) gives a good perspective
on the research and clinical management
as well as benefits ascribed to stem cells
in brain diseases. From their own points
of view with large experience on neuronal
progenitor cells the authors review cur-
rent advances in the field and also discuss
future directions to improve and manage
stem cell therapies in brain diseases. This is
very useful and could pave the way for bet-
ter designed and well-structured clinical
trials.
A recent example to mention in
this regard is the multi-center, open-
label, fetal cell TRANSEURO PD trial
in which 150 patients are presently
enrolled (http://clinicaltrials.gov/show/
NCT01898390). Previous fetal cell trans-
plants in Parkinson’s Disease patients (PD)
started in 1987 and the results of these
have varied from positive outcomes in
small open label trials, to mixed results
in two double-blind, placebo-controlled
clinical trials. This then in 2003 led to a
halt with this approach that was followed
by a reassessment by scientists and doc-
tors of the potentials and the future of
cell transplantations in PD (Inoue et al.,
2014). Recent optimization of the meth-
ods with major technical improvements in
cell derivation and use of alternative stem
cell sources including human Embryonic
Stem Cells (hESCs), and a careful revi-
sion of past trials, appropriate patient
selections, tissue placement and design
such as done in TRANSEURO PD trial
has led to purer concentrations of early
differentiated dopamine cells that may be
ideal for transplantation (Barker et al.,
2013; Bega and Krainc, 2014).
In their paper Viero et al. have sum-
marized their data with two human cell
lines, hESCs CCTL14 and the SPC-01
neural stem cell line derived from fetal
spinal cord. They have characterized these
cells by combining several experimental
approaches (FACS, immunocytochem-
istry, electrophysiology and RT-PCR).
They then also showed positive results
using these cells in transplantation stud-
ies, for the hESC line in stroke injury,
and for SPC-01 in spinal cord injury
(Viero et al., 2014). To accomplish this
the authors have carefully analyzed major
problems that are encountered in trans-
plantation studies such as the careful
characterization of the stem cells, their
transplantation techniques, and their cel-
lular reactions in grafted brain tissue.
The authors have further discussed cru-
cial matters, such as possible teratoma
formation, karyotype analysis, cell viabil-
ity, choice of gene expression markers for
progenitor cells before and after differen-
tiation, mycoplasma testing, and quality
control of culture conditions and media.
The manuscript presents a summarizing
figure with the flowchart for the suc-
cessful use of stem cells in the nervous
system and with regenerative potentials in
brain diseases. This paper builds a bridge
between research scientists and clinicians
to perform transplantation studies in the
future. With its clarity of thoughts and
clear concepts it will also no doubt lessen
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the confusions in the field and help to
avoid inflamed debates on clinical trials,
such as the Stamina one presently going on
in Italy (Cattaneo and Corbellini, 2014).
In this context distinguished researchers
Cattaneo, Bianco, and De Luca have
strongly advocated the use of rigorous
scientific and medical standards for the
introduction of new stem cell treatments
into the clinics. For this they have recently
been endowed with the Public Service
Award given by the International Society
for Stem Cell Research (http://www.
isscr.org/home/annual-meeting/2014annu
almeeting/program/2014-awards).
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